trial

The Gut Metagenome Research of Schizophrenia

NCTId NCT02708316
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Unknown
Enrollment 200 (estimated)
Sponsored by First Affiliated Hospital Xi'an Jiaotong University
Primary completion 2022-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
200 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2016-04
Primary completion
2022-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
sequencing faecal metagenome

Sponsors

First Affiliated Hospital Xi'an Jiaotong UniversityLead Sponsor
Rehabilitation Hospital of Bao Ji CityCollaborator
Center Hospital of Xian Yang CityCollaborator
Mental Health Center of Wei Nan CityCollaborator

Investigators

1
Xiancang Ma, MD,PHDPrincipal Investigator

Sites

1 total
Xi'an, China

Facts & assertions

4 sourced
Enrollment
200
Phase
NA
Primary Completion Date
2022-12
Status
UNKNOWN
relationships
The graph out of here
drug
sequencing faecal metagenome
drug
lead_sponsor
First Affiliated Hospital Xi'an Jiaotong University
company
collaborator
Rehabilitation Hospital of Bao Ji City
company
Center Hospital of Xian Yang City
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Xiancang Ma, MD,PHD
person